NLS

Thermo Fisher Scientific has announced a definitive agreement to acquire Clario Holdings, a provider of endpoint data solutions for clinical trials, from a shareholder group led by Astorg and Nordic Capital, Novo Holding and Cinven, for USD 8.875 billion in cash at close plus potential additional earnout and other payments in the future, largely dependent on performance.

The acquisition of Metsera, including its early and development-stage incretin and non-incretin analogue peptide programmes, would provide Novo Nordisk the opportunity to maximize the potential of Metsera’s complementary portfolio and capabilities, it states.

As part of this process, the company has initiated the statutory consultation required under Swedish employment law regarding a proposed reduction of six positions, which accounts for about 20 percent of its current workforce in Sweden.

Karolinska ATMP Center and ATMP Center Uppsala have signed a letter of intent to deepen cooperation in the rapidly growing medical field of advanced therapies (ATMP), which includes medicines based on cells and genes.

FluoGuide is in advanced negotiations with a world leading medical technology company on a collaboration agreement within head and neck cancer surgery where the aim is to optimize the usage of imaging systems and FG001 to enable better treatment for patients with cancer.

Helen Tayton-Martin will take up her new position on November 24, 2025, and simultaneously step down from Evaxion’s Board of Directors.